CRL earnings date and last-quarter result: last quarter beat, P/E -58.32. Updated 2026-07-23.
Charles River Laboratories International (CRL) Research Hub
Charles River Laboratories International (CRL) trades on NYSE, US in the Healthcare (Medical - Diagnostics & Research) sector. As of 2026-10-26, shares last closed at 357.27 USD (+3.45%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -58.32, market cap 10.63B. This hub links to the full technical, earnings and options research available for CRL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Diagnostics & Research) |
|---|---|
| Exchange | NYSE, US |
| Last close | 357.27 USD (+3.45%) |
| 52-week range | 178.92 USD – 357.77 USD |
| Trend regime | Range |
| 14-day RSI | 77.6 (Overbought) |
| Trailing P/E | -58.32 |
| Market cap | 10.63B |
| Dividend yield | 0.00% |
Available research for CRL
Covered Call on CRL: how it works, illustrative setup around the real 357.27 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRL: how it works, illustrative setup around the real 357.27 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRL: how it works, illustrative setup around the real 357.27 USD price, max profit/loss, breakeven and when to use it. Educational.
CRL technical analysis: range, last 357.27 USD, RSI 77.6, 52w range 178.92 USD–357.77 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CRL in?
Charles River Laboratories International (CRL) is classified under Healthcare (Medical - Diagnostics & Research), listed on NYSE, US.
Is CRL in an uptrend or downtrend?
As of 2026-10-26, CRL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRL's trailing P/E ratio?
CRL's trailing P/E is -58.32, with a market cap of 10.63B. See the earnings research page for full valuation detail.